We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.79%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$280M
AUM Growth
–
Cap. Flow
+$264M
Cap. Flow %
94.32%
Top 10 Hldgs %
44.86%
Holding
69
New
69
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.8M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$19.8M
3
BIIB icon
Biogen
BIIB
+$13.7M
4
ABBV icon
AbbVie
ABBV
+$11.1M
5
THOR
THORATEC CORPORATION
THOR
+$10.8M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 72.98%
2 Financials 1.53%
3 Industrials 0.94%
4 Technology 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CO
51
DELISTED
Global Cord Blood Corporation
CO
$1.5M 0.54%
+374,611
New +$1.49M
VRTX icon
52
Vertex Pharmaceuticals
VRTX
$126B
$1.49M 0.53%
+20,000
New +$1.39M
INFI
53
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.33M 0.47%
+96,000
New +$1.36M
WX
54
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$1.29M 0.46%
+33,500
New +$1.06M
MDCO
55
DELISTED
Medicines Co
MDCO
$1.25M 0.45%
+32,500
New +$1.16M
CBST
56
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$1.21M 0.43%
+17,500
New +$1.13M
WCG
57
DELISTED
Wellcare Health Plans, Inc.
WCG
$1.16M 0.42%
+16,500
New +$1.15M
ICPT
58
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.13M 0.4%
+16,500
New +$953K
NVAX icon
59
Novavax
NVAX
$1.31B
$1.13M 0.4%
+11,000
New +$777K
AVNR
60
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$1.01M 0.36%
+300,000
New +$1.24M
XNPT
61
DELISTED
XENOPORT, INC.
XNPT
$1.01M 0.36%
+175,000
New +$947K
AIRM
62
DELISTED
Air Methods Corp
AIRM
$992K 0.35%
+17,000
New +$847K
ALKS icon
63
Alkermes
ALKS
$8.25B
$945K 0.34%
+23,250
New +$859K
EXEL icon
64
Exelixis
EXEL
$13.4B
$920K 0.33%
+150,000
New +$826K
CADX
65
DELISTED
CADENCE PHARMACEUTICALS, INC COM STK
CADX
$810K 0.29%
+89,500
New +$646K
ACAD icon
66
Acadia Pharmaceuticals
ACAD
$5.03B
$785K 0.28%
+31,418
New +$741K
NKTR icon
67
Nektar Therapeutics
NKTR
$2.58B
$738K 0.26%
+4,333
New +$699K
ETRM
68
DELISTED
EnteroMedics Inc.
ETRM
$714K 0.26%
+333
New +$537K
ISEE
69
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$641K 0.23%
+19,800
New +$587K
1 2
3

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2013 Portfolio in Review

Q4 2013 is the first quarter with a 13F filing on record for Rock Springs Capital Management, which disclosed 69 positions worth $280M. Its ten largest holdings account for 45% of the portfolio.

Its largest position is Gilead Sciences: 285,000 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2013 buy was Gilead Sciences: 285,000 shares worth $21.4M.
  • Rock Springs Capital Management's ten largest holdings make up 45% of its $280M portfolio in Q4 2013.
  • Rock Springs Capital Management disclosed 69 positions in Q4 2013, its first 13F filing on record.

Based on Rock Springs Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.